N-(1-azabicyclo[3.2.2]non-3-yl)-thieno[3,2-b]pyridine-5-carboxamide | 508203-42-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: N-(1-azabicyclo[3.2.2]non-3-yl)-thieno[3,2-b]pyridine-5-carboxamide
• 英文别名: N-(1-azabicyclo[3.2.2]nonan-3-yl)thieno[3,2-b]pyridine-5-carboxamide
• CAS: 508203-42-7
• 化学式: C₁₆H₁₉N₃OS
• 分子量: 301.412
• InChiKey: PDTGACMGHOMNHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  73.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
  申请人：——

  公开号：US20030153595A1

  公开（公告）日：2003-08-14

  The invention provides compounds of Formula I: 1 wherein Azabicyclo is 2 3 These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.

  该发明提供了Formula I中的化合物：1其中Azabicyclo为23这些化合物可以是药用盐或组合物的形式，或者是它们的外消旋混合物或纯对映体。Formula I中的化合物在已知涉及α7的药物中是有用的。
• Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
  申请人：Walker Patrick Daniel

  公开号：US20050234092A1

  公开（公告）日：2005-10-20

  The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

  本发明提供了I式化合物：其中Azabicyclo为这些化合物可以是药物盐或组合物，外消旋混合物或其纯对映体。式I的化合物在已知α7参与的制药领域中是有用的。
• Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
  申请人：Hurst S. Raymond

  公开号：US20060142349A1

  公开（公告）日：2006-06-29

  The present invention provides methods for identifying compounds useful in modulating α7 nicotinic acetylcholine receptors. The invention also provides compounds that prevent, suppress or inhibit desensitization of an α7 nicotinic acetylcholine receptor, and which resensitize such receptors. Pharmaceutical compositions, and methods of treatment, particularly in regard of neurological diseases are also described.

  本发明提供了鉴定有助于调节α7烟碱乙酰胆碱受体的化合物的方法。本发明还提供了防止、抑制或抑制α7烟碱乙酰胆碱受体脱敏以及使这种受体重新敏化的化合物。本发明还描述了药物组合物和治疗方法，特别是治疗神经系统疾病的方法。
• AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1432707B1

  公开（公告）日：2012-03-28
• US6911543B2
  申请人：——

  公开号：US6911543B2

  公开（公告）日：2005-06-28